Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)

NCT05403541 is registered in ClinicalTrials.gov with Immunovant Sciences GmbH as lead sponsor.

NCT NCT05403541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05403541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multi-center, Randomized, Quadruple-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Batoclimab as Induction and Maintenance Therapy in Adult Participants With Generalized Myasthenia Gravis (gMG)
Lead sponsor
Immunovant Sciences GmbH
Phase
Phase 3
Overall status
Terminated
Start date
June 27, 2022
Completion date
August 7, 2026
Enrollment
233 (actual)
Sites
93

Conditions

As the registry lists them; a condition with its own page is linked.

generalized myasthenia gravis